Amendment File - All Questions 7-6-21.docx

Cumulative Solicitation Questions Below are the questions submitted by prospective vendors regarding the NPV GEN IV Solicitation SPE2DX-20-R-0001 (posted on June 3rd, 2021) prior, during, and after the pre-proposal conference dated June 17th, 2021. DLA Troop Support has provided a response below each question.

Note: The answers to vendor questions provided in this attachment are provided solely for informational and clarification purposes only and do not change or alter any solicitation requirements. In the event of a discrepancy between the answers and the solicitation, the solicitation will take precedent. The answers provided are merely informational and not binding.

Topic: Specialty

1. Criterion #1: states “initiated / maintained by a specialist”. Specialty drugs are increasingly entering traditional primary care space. For example, Praluent, Repatha are managed by cardiologists and are on the list, but Oriahnn managed by OB/GYN is not). How will the DoD look at specialty drugs entering primary care?

i. The Government acknowledges that many of these specialty drugs can be handled by primary care. While Oriahnn (used in the example above) may not meet Criterion #1, it could still be considered specialty and eligible for the specialty distribution fee as long as it meets 4 of the 6 Criterion stated under the Specialty Pharmaceuticals section on page 25 of the SOW.

2. Criterion #2: The second criterion in the Specialty definition explicitly excludes "self-administered" products and oral products, however the majority of drugs on the DoD list are self-administered and many are oral therapies. Is this a typo and should the second criterion instead read “generally injectable, oral and/or self-administered”?

i. This is not a typo. Based on DLA’s market research, the industry generally uses a set of criteria to classify specialty drugs which admittedly varies across organizations. DLA choose to use seven of the most common recurring criteria.

3. Criterion #3: Please confirm that consistent with industry standards special handling includes cold chain (refrigerated or frozen), limited distribution and REMS? Also, are there any other attributes which DLA considers as special handling?

i. DLA acknowledges that criterion 3 is meant to be consistent with the industry standards of special handling. Criterion 3 includes refrigerated, frozen, chemo, other biohazard, REMS, etc. Limited distribution items may also qualify under the special handling criterion as the manufacturer has greater oversight over the handling of these items throughout the supply chain.

4. Criterion #4: Please confirm that consistent with industry standards the $6,000 annual cost is calculated using WAC and not contract pricing?

i. The $6000 annual therapy cost is based on WAC

5. Criterion #5: Please confirm that anything ordered by or delivered to a specialty pharmacy or mail order pharmacy is considered a “non-traditional channel”. Are there other channels that would be considered non-traditional?

i. DLA does not concur with this assessment of Criterion 5. This criterion points to items that require unique distribution (i.e. REMS as defined by the FDA at https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems ).

6. Will all biosimilars be considered specialty per DoD’s definition?

i. If items meet the criteria in the solicitation, the vendor can submit them for consideration in the specialty category.

ii. Per our SOW “The PS may also submit items for consideration, with appropriate documentation that the items meet at least four of the specialty characteristics identified above.”

7. Why does the DoD’s specialty list only have one biosimilar (Zarxio) when there are nearly 20 biosimilars approved thus far?

i. The provided list is a baseline and includes specialty items DHA expects to order under this contract. New biosimilars are being approved continuously throughout the industry. As such, the SOW allows for NDC’s to be added at the request of the PS and after a review from the Contracting Officer.

8. There seems to be an inconsistent approach to self-administered drugs. For example, the HIV drugs (Biktarvy, Truvada, Atripla) are not on the list, but Hep C drugs (Harvoni, Epclusa) are included. Can the DoD confirm that HIV drugs should be on the specialty list?

i. The specialty list is a living document and will be reviewed on a regular basis (not less than once per month) and items may be added or deleted depending on market conditions. The PS may also submit items for consideration, with appropriate documentation that the items meet at least four of the specialty characteristics identified above.

9. How will the DoD determine which provider administered drugs are Specialty vs. not? In the DoD Specialty list, for example, Keytruda and Imfinzi are not included but Humate and Advate are included – however, all four drugs are considered specialty drugs in the commercial market

i. The list is a living document. NDC’s may be added to the list after Contract Officer review.

10. Can the DoD confirm that if a brand molecule has been designated as Specialty on the Specialty List, then all generic versions of that branded drug would also be considered Specialty and added to the Specialty List? There seems to be an inconsistency with some generics on the Specialty list and other generics that are not, but the corresponding innovator brand is on the list. Generics to Zytiga, Tecfidera and Sensipar (abiraterone, dimethyl fumarate, and cinacalcet (respectively) are listed; however, the generics to Hycamtin, Northera, and Cystaran are not listed.

i. This is a list of what the Government deems to be specialty. Items may be added at the request of the PS and after approval from the Contracting Officer.

11. RFP states "During the base and subsequent option periods, the Government reserves the right to reevaluate and remove specific specialty pharmaceuticals from the NPV contract." Please confirm this right will not be used to reclassify a drug from specialty category to brand category

i. Confirmed

12. Will this remove the specialty volume fully from the DoD’s purchases from the prime vendor?

i. Correct. Specialty drugs would be taken out of the contract all together. The NPV would be notified of this decision 60 days prior to the start of a contract period if this decision were made.

13. Please confirm that the volume in the specialty list file needs to be added to the day-to-day file for a complete view of volume for the contract period.

i. The specialty list will not be added to the day-to-day file as the usage is on Attachment 3 is only estimated and not based on historical NPV sales. DLA added the estimated volume to give offerors an idea of what could be ordered.

14. What timeframe is the specialty list file from?

i. 01JAN20 – 31DEC20

15. With specialty being a new component to this agreement how is that represented in the FY19 data?

i. Although not all of the anticipated specialty sales is captured in the FY19 data, DLA did include anticipated specialty utilization in Attachment 3

16. Specialty pharmaceuticals (Section 1.E – pg 25) - The SOW indicates there will be separate administrative contract numbers for specialty and brand/generic for tracking purposes. Does this indicate specialty orders will be ordered on separate orders from brand /generic?

i. Yes, items classified as specialty pharmaceuticals (attachment 3) will be ordered separately under its own administrative contract.

17. Attachment 3 NPV GEN-IV Specialty List– Specialty products.

i. Is this specialty list a subset of the FY19 sales by NDC (attachment 5)?

1. No, the specialty list featured in Attachment 5 is the initial listing of the NDC’s that will be eligible for the separate specialty distribution fee.

ii. If yes, why are there some items in the specialty list that are not in attachment 5?

1. N/A…see answer above.

iii. If no, there are some items that are on both attachment 3 and 5, which price would apply to these items?

1. If an item is on the specialty drug list (attachment 3), then it is eligible to receive the specialty distribution fee.

18. Please confirm that volume form the new Specialty Pharmacy locations volume is included in the pricing evaluation sales on page 104?

i. No this is not included. Unfortunately, volume is only estimated as specialty pharmacy locations will be new to GENIV and are not known yet.

19. Please confirm if the Specialty File includes expected volume for both TMOP and the Specialty Pharmacy locations or is it just the new Specialty Pharmacy locations?

i. Attachment 3 is an estimated volume for specialty pharmaceuticals. Due to specialty being relatively new DLA does not have robust historical sales data for specialty.

20. DoD has provided specialty pharmaceutical volume in terms of a dispensed volume. To understand the impact of this part of the DoD volume, distributors need to understand it in terms of volume of product purchased as packaged by the manufacturer (not as dispensed by a pharmacy). To ensure potential bidders are operating with the same understanding, can the DoD provide the specialty volume by units purchased and not dispensed? For many of these drugs it isn’t possible for a distributor to do this conversion.

i. DLA was able to obtain an estimate of units purchased and has included this data in Attachment 3. A revised version of Attachment 3 will be included with Amendment 0001. Please note that the estimated total purchased volume and amount dispensed are not based entirely on historical NPV sales data. These figures are both points of reference as a majority of these specialty pharmaceuticals are currently purchased outside of the NPV program and may not be representative of quantities or products purchased under the NPV GENIV contract.

Topic: Cyber Security

21. Does the Government consider this procurement to require additional information system security measures or recommend other information systems security measures, in addition to those explicitly included in the solicitation, for use by the perspective contractor on this procurement?

i. As each vendors information technology can differ and there are various way to ensure cybersecurity, the Government does not mandate any additional measures beyond those listed in the solicitation, particularly Section 12 of the Statement of work and the NIST 800-171 publication requirements. Beyond the solicitation requirements, vendors should review their information technology infrastructure to assess if additional vulnerabilities exist and require further measures and/or b be beneficial to the vendors security. Beyond commercial best practices for cybersecurity, vendors can review DoD’s Project Spectrum which was designed to help vendors understand CMMC requirements which are largely based on NIST 800-171. Project Spectrum is an initiative supported by the DoD Office of Small Business Programs but accessible to all vendors at https://projectspectrum.io. Project Spectrum provides information, training, and risk assessments to help vendors improve cyber readiness and comply with DoD requirements. The site does contain NIST specific content and guides on addressing specific IT and cybersecurity issues. Please note that CMMC does not currently apply to this procurement nor is Covered Defense Information expected as part of contract performance but the website can be used as a resource to gain further information on cybersecurity, NIST and where DoD is heading with cybersecurity.

22. Please identify the other applicable safeguarding or cyber incident reporting requirements as required by other applicable clauses of this contract, or as a result of other applicable U.S. Government statutory or regulatory requirements that are relevant to this procurement.

i. Vendors must review the entire solicitation, including all clauses/provisions and the statement of work, to identify any applicable safeguarding, cybersecurity and IT requirement as some requirements not specifically tied to these topics may impact cybersecurity. Some solicitation clauses/provisions that directly deal cybersecurity are:

1. Clause - 52.204-23 Prohibition on Contracting for Hardware, Software, and Services Developed or Provided by Kaspersky Lab and Other Covered Entities (JUL 2018)

2. Provision - 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (OCT 2020)

3. Clause - 52.204-25 Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment (AUG 2020)

4. Provision - 52.204-26 Covered Telecommunications Equipment or Services—Representation (OCT 2020)

5. Provision - 252.204-7016 Covered Defense Telecommunications Equipment or Services—Representation (DEC 2019)

6. Provision - 252.204-7017 Prohibition on the Acquisition of Covered Defense Telecommunications Equipment or Services—Representation (MAY 2021)

7. Clause - 252.204-7018 Prohibition on the Acquisition of Covered Defense Telecommunications Equipment or Services (JAN 2021)

23. Please confirm that the Section 12 Cybersecurity Requirements applies to the entirety of the offeror’s information technology infrastructure that is required to perform the requirements of the contract, versus strictly those information systems that process, store, or transmit Covered Defense Information

i. Yes, the cybersecurity requirements apply to all vendor information systems that support the contract and not just those that may handle Covered Defense Information. Although the NIST documents do speak to Covered Defense information, for purposes of this procurement, vendors shall look at their entire information technology infrastructure that is required to perform the requirements of the contract. This includes assessing all information technology systems that would stop contract performance or degrade it to a degree where the vendor could not meet contract requirements if compromised by a cyber-attack. It is not expected, that any Covered Defense Information will be provided to the vendor or generated as part of contract performance.

24. Is there a negative summary level score or range for the NIST SP 800-171 security assessment that would result in a bidder being determined to be non-responsible?

i. There is no specific score or range that would make a vendor unacceptable if the vendor has complied with the solicitation requirements in the instructions to offerors section and the evaluation section. That includes, for each requirement that is not met prior to contract award, the vendor must provide details on the reason that prevents meeting the requirement and how they will meet the requirement in the future. The plan for meeting each requirement after award shall be reasonable and realistic.

All Other Questions

25. RFP states states (p26) "If the government elects to use a third-party vendor, it will become the single source for the specialty designator" Please confirm that changes to the definition or list of drugs and its application will be done via 52.212-4’s changes clause.

i. Yes, a modification will be issued if a third party vendor is used exclusively to identify specialty pharmaceuticals under the NPV GENIV contract.

26. What flexibility does the TPharm contractor have to select items when multiple items within a single class of product are on formulary?

i. It would be the same flexibility as they have today under NPV GENIII. The TPHARM5 contractor would simply submit a NDC change request.

27. Please confirm that DoD will not utilize “white bagging” or “brown bagging” of provider administered drugs through the NPV contract. "White bagging" means that provider administered products are shipped by the pharmacy directly to the provider office. “Brown bagging” refers to the practice of shipping provider administered products to the patient, who takes them to the provider for administration. If adopted, both practices would shift products from the PPV-Global contract to the NPV. The specialty products and volumes provided by DoD do not appear to be reflective of future use of these practices.

i. Currently under the TRICARE Pharmacy Program there are limited situations, as requested by the provider and/or beneficiary, where “white bagging” or “brown bagging” services are provided by the pharmacy contractor. However, as the TRICARE pharmacy and medical benefits evolve these services may be more widely offered in the future. If the TRICARE benefit changes, the Defense Health Agency (DHA) will coordinate with DLA to ensure the NPV contractor and other applicable DLA-managed contractors are provided advanced notice of this change and can accommodate the shift in utilization.

28. What is the difference is in roles of DLA and DHA? Does DHA dictate what ESI can buy? Why does ESI not move to a national contract when it comes out? What does DHA do in their role different than DLA?

i. DHA is the customer and they manage and maintain the Tricare formulary. DHA ultimately dictates what ESI (their vendor) can buy from DLA’s NPV contract. DHA owns the TPHARM5 contract and oversees the TPHARM5 contractor’s buying activities. DLA owns the NPV contract and simply ensures that the NPV fills the orders from the TPHARM5 contractor.

29. The directions for submission of a technical proposal imply that bidders are not to submit a traditional technical proposal that addresses the technical requirements set forth in the Statement of Work. Can the government please confirm that all bidders are to submit is a “yes or no” response to the technical areas set forth in Tab 1(E) of the proposal?

i. The contractor must submit the items requested in the solicitation requirements

ii. All bidders are to submit yes or no responses to the statement of work requirements set forth in tab E of the proposal

30. Should the determination be made that there is a need for a reverse auction, could you please provide an approximate timeline of when that would occur. Could you also review the process since there will be the ability to submit multiple distribution fees per option period?

i. DLA cannot provide an approximate time frame. It will be conducted after evaluations have been completed.

ii. The commercial reverse auction service provider or government representative conducts training for offerors. Offerors receive training through written materiel, the commercial reverse auction service provider’s website, or other means.

iii. The reverse auction service provider is Procurex Inc.

31. On page 5 section 7. Product Pricing it references Express Scripts Inc. as being awarded the TPharm contract. Is that stating that they are currently the awardee or is that in fact confirming that ESI has been awarded the TPharm5 contract?

i. The TPHARM5 contract has not yet been awarded. ESI is the current TPharm contractor. Caution Notice, section 7, paragraph 4 (page 5) has been revised at part of Amendment 0001.

32. On page 6 National Prime Vendor Distribution Fees it states a 5.76% annual increase based on forecasted sales. Can you please clarify if that is based on sales dollars or product quantities? Additionally, please clarify if that percentage growth is applied evenly across all products or accounts for different growth in particular products/categories? Can you please confirm that this is how you are evaluating the offer as well?

i. Each year sales were increased by the average YoY % change of PPI 32541 and calculated based on total sales.

ii. Yes, DLA is evaluating the offers based on that sales data. See the section “how competing offers are being evaluated” on page 104 to 105 of the solicitation.

33. The utilization provided in Attachment 1 is based on FY19 Data. Can you please confirm that the provided utilization data is based on actual replenishment from FY19?

i. This sales data was historical FY19 sales.

34. Is it possible to get FY18, FY20 and FY21 year to date usage data? Understanding that FY20 was impacted by COVID19 and FY21 not complete data.

i. DLA cannot provide FY21 sales as the data is still be processed. DLA will address this via Amendment 0001 by providing additional data in Attachment 5 for FY18 and FY20 sales.

35. Is it possible to get a sense of the utilization broken down by location?

i. The locations may change with who is awarded the TPharm5 or GENIV contract.

36. Are you able to confirm any of the up to 12 ship to locations?

i. The number of locations may change with who is awarded the TPHARM5 contract. It will not be more than 12

37. Are the required delivery times known, and can those be shared at this time?

i. Specific delivery times are not yet known. Delivery times will need to be coordinated with the TPHARM 5 contractor during the implementation period after the NPV GENIV contract is awarded.

38. Attachment 1 NPV GEN IV Day-to-Day Requirements Spreadsheet lists 1778 NDCs with total sales of $53,244,931.58. During what time period did these sales occur? Is $53,244,931.58 the average daily sales? Why are there only 1778 NDCs in this list when there are 10,096 NDCs/line items in Attachment 5, which shows the 2019 NPV GEN III FY 2019 Sales of $2,907,955,249?

i. The day-to-day attachment consists of the average weekly sales per NDC for FY 18, 19, and 20. The list was further refined to include only the NDCs with significant sales. This was done to streamline the list and filter out small one-off orders. This also explains why the total is drastically different from Attachment 5, which is a entire fiscal years worth of sales.

39. Attachment 2 WRM Requirements Spreadsheet lists 593 NDCs [NOTE: Is QUI (column G) the quantity the offeror must have on hand?

i. Per Section 11. War Readiness Materiel (WRM) Back- Up Requirements (PS- Only) the PS will not be required to store the quantities displayed on attachment 2. Rather, the PS is confirming the quantities that they will be able to supply for the WRM program.

40. Attachment 3 Specialty Drug List contains 1147 NDCs for specialty items. Why are some of the NDCs in Attachment 3 not included in Attachment 1?

i. The NDC’s displayed in Attachment 3 are all of the NDC’s that the Government currently considers to be specialty. It is not representative of historical sales of the NPV contract which is featured in Attachments 1 and 5.

41. Attachment 5 NPV GEN III FY 2019 Sales lists 10,096 line items with total dollar value sales of $2,907,955,249. The estimated expenditure for the 24-month base period under the new contract is $7.23B—which is 2.5 times higher than the $2.9B FY 2019 sales. With the expansion of the NVP GEN IV contract to include sales to a network of specialty pharmacies can you elaborate on how the new specialty estimated spend is calculated?

i. The 2.9B is for 12 months of sales.

ii. The 7.23B is for a 24 month base period beginning in 2022

iii. DLA included a year over year increase for the years not completed yet (2021 and 2022).

iv. DLA estimated 20% of sales volume for specialty drugs which is compounded with the year over year increase based on PPI.

42. Programs Items (Section 1.D – Pg 25) Is Big 4 contract pricing for various NDCs accessible under this SOW?

i. The TPharm5 contractor will be eligible for Big 4 pricing. Section 1(D) has been revised via Amendment 0001 to include Big 4 pricing.

43. Ordering Facilities (Section 1.F – pg 26) Can a list of the up to 12 TRICARE Pharmacies’ delivery addresses be provided?

i. The TPHARM5 contract has not been awarded yet so it may change.

44. Can this list indicate if the locations are Mail Order, Specialty / Retail sites?

i. The TPHARM5 contract has not been awarded yet so it may change.

ii. Each ordering site will have two admin contracts for mail order and specialty.

45. What is the annual total volume by site? Units and dollars

i. The TPHARM5 contract has not been awarded yet so it may change.

46. What is the average number of lines per delivery?

i. Since the inception of NPV GEN III there has been about 280k total orders with an average of 20 lines per order, with the largest order being around 700 and the smallest containing 1 line.

47. Catalog Requirements (Section 2.B.2 – pg 28) Can the EDI implementation guide be provided?

i. Please visit https://www.medical.dla.mil/ for the EDI implementation guide.

48. What is the monthly average number of emergency orders and number of lines per order?

i. There is an average of 19 reported emergency deliveries per month across all 3 current TMOP facilities. Emergency deliveries typical consist of 1 line orders. Please note that per Section F. Order Placement/Delivery 10. “No Charge” Emergency Orders on Page 41 of solicitation SPE2DX-20-R-0001, the NPV is only expected to “provide a maximum of two emergency shipments per month to each of the TPharm ordering facilities at no additional transportation/handling charges to the TPharm ordering facility. Any additional emergency shipments requested by the TPharm ordering facility more than two per month can be charged to the TPharm ordering facility, including all applicable transportation and handling costs, as agreed to between the TPharm ordering facility and the contractor”.

49. Wide Area Workflow (Section 2.M.2 – pg 46) Can you please elaborate on how the shipment ID will be utilized?

i. The shipment number is required on all invoices and on the DD Form 250.

ii. A shipment number contains three alpha and four numeric characters, in the sequence AAA0000. An eighth character (Z) is used to designate the final shipment. Many contractors use the first two alpha characters to indicate their company name. The third alpha character can indicate the location from which the material is shipped. For example, the company General commodities would use GCD as alphas for all shipments from Dallas, and GCA for all shipments from Austin. The same alpha prefixes must not be used for shipments from different locations.

iii. The four numeric characters indicate consecutive shipments from each location, example, GCD0001, GCD0002, GCA0001, GCA0002. The final shipment for the entire contract must carry a "Z" suffix - GCD0003Z or GCA0003Z. We discourage the use of alpha characters I or O as they are too easily mistaken for the numbers 1 or 0.

50. Shortages/ Other Discrepancies (Section 2.O.6, pg 48) Is a cycle count verification acceptable before issuing credit?

i. Yes, a cycle count verification would be considered acceptable.

51. War Readiness Material (WRM) Back up Requirements (Section 11, pg. 74) What is the volume of backup WRM orders from the last 12 months?

i. Unfortunately, the WRM program was not utilized during the NPV GENIII contract. Therefore, no sales data is available and all sales figures provided are estimates. Please note that per Section 11(D)(4), the NPV PS shall not be subject to a minimum fill rate level although it should make every effort to fill any WRM order received.

52. FAR 52.212-1 Addendum #3 Solicitation Provisions – Volume 1 Non-Price Proposal – Submission- Technical Responses – (p.95)

i. Demonstration of capability to meet day to day requirements - Can the full weekly volume for the Government site visit be satisfied by inventory across an offerors’ distribution network?

1. Please refer to Amendment 0001 for the revision to the site visit requirement.

ii. Demonstration of capability to meet WRM back up requirements - Can the full weekly volume for the Government site visit be satisfied by inventory across an offerors’ distribution network?

1. Please refer to Amendment 0001 for the revision to the site visit requirement.

iii. Can you please clarify being able to support quantities by site visit? We would adjust our replenishment ordering from manufacturers if awarded the business.

1. Please refer to Amendment 0001 for the revision to the site visit requirement.

53. On MP3, the presentation said it applies to unavailable OR brand items. That is different than the current RFP language. Can DLA explain how it applies to brand items? Will the Tpharm contractor have the ability to pull brand items even if available?

i. Please refer to Section 7. DHA Market Priced Pharmaceutical Program (MPPP). Under Section 7, the SOW states “the TPharm contractor may recommend to the DHA sustainment offers of Trade Agreements Act (TAA) compliant agent(s) to dispense at TMOP or specialty pharmacy(ies) where supply sources are not stable or are unavailable through the NPV (PS & BS). Such offers may address situations when the only alternative agents available from the NPV are branded agents, or agents otherwise treated as brand, which are more costly to the Government compared to generic agents available in the commercial market.” This is alignment with what was presented during the preproposal conference. If only branded NDC’s are available, the TPharm5 contractor may submit an MPPP offer to the DHA for a less costly generic.

54. The six-hour delivery requirement for specialty items is not viable as most of these items are distributed from very few distribution centers. Moreover, it is unreasonable to be asked to commit to this requirement without knowing the number, type, and location of TPharm facilities. Please confirm the 6-hour requirement applies solely to brand/generic items.

i. The six hour delivery requirement for emergency orders has been revised under Amendment 0001 to only include stocked items. Items requiring drop shipment will be excluded from this requirement.

55. When will the TPHARM contract be awarded?

i. The TPHARM5 contract is managed by the DHA and therefore DLA does not have an accurate timeframe as to when the TPHARM5 contract will be awarded.

56. You mentioned being willing to provide FY20 Utilization, would you also provide FY18?

i. Yes. Additional tabs will be added to Attachment 5 to include FY18 and FY20 sales data. This revised attachment will be issued with Amendment 0001.

57. How does the site visit process work for reviewing required on hand quantities? Does DLA select the site or does the wholesaler?

i. The site visit requirement has been revised in Amendment 0001. A site visit will now occur only if determined necessary by the Government. If the Government determines that a site visit is necessary, then it will reach out to the offeror no earlier than 30 days after the solicitation closing date. The Government will work with the offeror regarding the site visit location.

58. In terms of data handling, is there an expectation that DLA data must be on independent tenants or can shared applications/middleware/DBs be used?

i. Please refer to Attachment 9 - NIST.SP.800-171(r2) Publication for further guidance.

59. Is the volume by order channel (EDI vs. Web). Can we get this historical breakdown?

i. Based on DLA’s data, there have been roughly 130,000 traditional EDI orders and approximately 67,000 PVWeb orders since the inception of the NPV GEN III contract.

60. Usage Data (Section 2.E – pg 38) Can usage data be provided by ordering location?

i. The TPHARM5 contract has not been awarded yet so locations may vary.

61. I will echo not knowing the delivery points, does create some challenges with ensuring capacity at servicing DCs and usage at sites.

i. DLA does not know who the TPharm5 contractor will be therefore it’s difficult to predict until TPHARM5 contract is awarded. DLA does not have that data at this time.

62. Page 88. (e) the statement on multiple offers being evaluated - Can you please clarify that you all are not looking for multiple offers from the vendors introducing alternative terms?

i. Please note that this is a Lowest Price Technically Acceptable acquisition, exception to terms and conditions may be deemed unacceptable and may be considered technically unacceptable. A Reverse Auction will be utilized if deemed necessary.

ii. Refer to page 91 of the solicitation Addendum to 52,212-1 Paragraph (e), Multiple offers

iii. Alternative commercial items may be considered for award on this acquisition if they are AB rated or considered a Bioequivalent generic.

63. FAR 52-212-1 and FAR 52.212-2: Demonstration of Technical Responses for Attachments #1 and #2. Will NDCs identified as “Unavailability Issues” due to manufacturer backorder, product recall, manufacturer discontinuation, and manufacturer restricted allocation, be excluded from the breadth and depth calculation? For example, if there are 1000 items in the file and 100 items are unavailable due to the outlined criteria, is the breadth and depth calculation now based on the population of 900 available items?

i. Yes, please refer to FAR 52.212-1 Addendum #3 Solicitation Provisions – Volume 1 Non-Price Proposal – Submission- Technical Responses (pages 95-96). DLA Troop Support will validate the responses in the “Unavailability Issues” column with the respective manufacturers. If DLA Troop Support is able to confirm with the manufacturer the provided reason the item will be excluded from the breadth and depth calculations.